The Doubao platform has launched a new AI programming feature, and the AI + low-code platform is expected to open up growth potential.

① The Doubao official WeChat account shows that the Doubao desktop and web versions have launched new AI programming features. ② Lyu Wei from Minsheng Securities stated that from 2021 to 2025, there will be an addition of 0.5 billion applications globally, and by 2024, 65% of applications worldwide will be developed using low-code platform models.

cls.cnJan 17 08:20

In 2024, a net loss is anticipated to exceed 0.6 billion; Hangzhou Century resorts to selling land to "ease its troubles" after financial fraud | Interpretations

① Hangzhou Century expects a net income loss attributable to shareholders of the listed company of 0.419 billion yuan to 0.629 billion yuan for the fiscal year 2024, with narrowing losses; ② Hangzhou Century was heavily fined by regulators for fabricating false content in the 2019 and 2020 annual reports as well as in the 2021 Convertible Bonds public issuance documents; ③ To alleviate cash flow issues, the company plans to sell assets.

cls.cnJan 15 20:22

An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.

① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.

cls.cnJan 9 21:38

Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.

A specific plan recognized by all relevant parties could not be formed.

wallstreetcnJan 7 16:23

Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.

① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.

cls.cnJan 6 23:59

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20